Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study

2009 ◽  
Vol 2009 ◽  
pp. 269-270
Author(s):  
W.H. Ludlam
2009 ◽  
Vol 70 (5) ◽  
pp. 757-768 ◽  
Author(s):  
Annamaria Colao ◽  
Paolo Cappabianca ◽  
Philippe Caron ◽  
Ernesto De Menis ◽  
Andrew J. Farrall ◽  
...  

2020 ◽  
Vol 11 (3) ◽  
pp. 4836-4846
Author(s):  
Mohsina Hyder K ◽  
Raja D ◽  
Jithin Mohan ◽  
Ponnusankar S

Currently, 314 million people in the world are Prediabetes, and it is predicted that around 500 million would be burdened by the year 2025. Continuing education of diabetes and its complications is crucial, but it should be accompanied with regular assessment of Knowledge Attitude and Practice (KAP) among the high-risk population. That would play a cost-effective role in prevention and control of the disease.This study was carried out to assess the Knowledge, Attitude and Practice among the newly diagnosed Prediabetes screened over selected districts of South India.This study was conducted through prediabetes screening camps over districts of Calicut, Wayanad and Malappuram in Kerala and The Nilgiris district in Tamilnadu from September 2017 to October 2019. A questionnaire survey was done as a part of a prospective open-label interventional study with 308 prediabetes individuals. Baseline characteristics of the participants were obtained, and their knowledge, attitude and practice regarding Prediabetes were assessed. The finding of the present study revealed 90% of the respondents had poor knowledge, 9% had average knowledge, and only 1% had good knowledge of Prediabetes. In the attitude assessment, only 1.9% had a strongly positive attitude, 14% had a positive attitude, 54% had neutral attitude while 17% had a negative attitude and 13% had a strongly negative attitude. Regarding healthy lifestyle practices, 35.4% had a deplorable practice that scored below 6. Around half of the population, 52.3% had poor practice, 12% had proper training, while only 0.3% had a perfect practice.Knowledge and practice regarding lifestyle modifications among prediabetes participants were found to be reduced. 


2011 ◽  
Vol 75 (5) ◽  
pp. 678-684 ◽  
Author(s):  
Z. Karaca ◽  
F. Tanriverdi ◽  
G. Elbuken ◽  
I. Cakir ◽  
H. Donmez ◽  
...  

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii297-iii297
Author(s):  
Sharon Gardner ◽  
Rohinton Tarapore ◽  
Jeffrey Allen ◽  
Wafik Zaky ◽  
Yazmin Odia ◽  
...  

Abstract H3 K27M-mutant gliomas often manifest as midline gliomas, have a dismal prognosis, and have no effective treatments. ONC201 efficacy has been shown in high-grade glioma preclinical models and durable responses with single agent ONC201 have been reported in adults with recurrent H3 K27M-mutant gliomas. These observations led to a Phase I pediatric clinical trial of ONC201 dosed by body weight. This multi-center, open-label, 3 + 3 dose-escalation and dose-expansion clinical trial (NCT03416530) for H3 K27M-mutant glioma or non-biopsied DIPG has 6 arms: arms A and E determine the RP2D in pediatric post-radiation (recurrent or not-recurrent) H3 K27M-mutant glioma patients with ONC201 administered as an oral capsule as well as a liquid formulation, respectively. Both arms have completed accrual. The study is currently enrolling newly diagnosed DIPG patients to determine the RP2D for ONC201 in combination with radiation (arm B). Dedicated assessment of intratumoral ONC201 concentrations in midline gliomas patients (arm C) and the effects of ONC201 in H3K27M DNA levels in circulating CSF (arm D) are currently enrolling patients. ONC201 as a single agent in patients with progressive H3K27M mutant tumors following irradiation (excluding DIPG/spinal cord tumors) was recently opened (arm F). Once the RP2D is confirmed, there is a dose-expansion cohort to confirm the safety, radiographic efficacy and survival with ONC201. The primary endpoints of arms A, B, and E have been established with the RP2D of 625mg scaled by body weight as a capsule or liquid formulation administered alone or in combination with radiation without incidence of dose-limiting toxicity.


2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 7540-7540
Author(s):  
David Belada ◽  
Katerina Kopeckova ◽  
Juan Miguel Bergua ◽  
Marc André ◽  
Ernesto Perez Persona ◽  
...  

7540 Background: Tafasitamab is a humanized, Fc-modified anti-CD19 monoclonal antibody that enhances antibody-dependent cellular cytotoxicity and phagocytosis. It is FDA-approved with LEN for adult patients (pts) with relapsed/refractory (R/R) DLBCL ineligible for autologous stem cell transplantation. First-MIND (NCT04134936) is a Phase Ib, open-label, randomized study of tafa + R-CHOP or tafa + LEN + R-CHOP in newly diagnosed DLBCL. Methods: Eligible pts were ≥18 years, treatment-naïve, with histologically confirmed DLBCL not otherwise specified, international prognostic index (IPI) 2–5 and ECOG performance status (PS) 0–2. Pts with known double- or triple-hit and transformed lymphoma were excluded. Treatment (Tx) comprised six 21-day cycles of tafa (12 mg/kg IV, Day [D] 1, 8, 15) + R-CHOP (arm A) or tafa (12 mg/kg IV, D1, 8, 15) + LEN (25 mg orally, D1–10) + R-CHOP (arm B). G-CSF and VTE prophylaxis was mandatory. Primary objective is safety; secondary objectives are ORR, PET-CR rate at end of Tx, PFS, long-term safety, pharmacokinetics, immunogenicity. Results: From Dec 2019 to Aug 2020, 83 pts were screened in Europe and the US; 66 were randomized (33 per arm). Data cut-off for this analysis: 9 Dec 2020; study is ongoing. Median age was 64.5 years (range 20–86). Overall, 30% (20/66) of pts were ≥70 years and many had high-risk disease: IPI 2 29%, IPI 3 46%, IPI 4 26%. ECOG PS: 47% of pts were ECOG PS 0, 44% PS 1, 9% PS 2. Most pts had stage III/IV disease (92%); 46% had bulky disease. All pts experienced a treatment-emergent adverse event (TEAE). Grade ≥3 neutropenia and thrombocytopenia occurred in 54.5% and 12.1% (arm A) and 66.7% and 30.3% (arm B) of pts, respectively (Table). Serious TEAEs occurred in 42.4% (arm A) and 51.5% (arm B) of pts. There were three deaths, unrelated to tafa and/or LEN (sepsis, urosepsis, and COVID-19 pneumonia). R-CHOP dose intensity was maintained in both arms. Among 60 pts who completed tumor assessments after cycle 3, ORR was 89.7% (arm A) and 93.5% (arm B). Conclusions: These data suggest R-CHOP + tafa or tafa + LEN is tolerable in pts with Tx-naïve DLBCL and that R-CHOP dosing is not affected. Toxicities are similar to those expected with R-CHOP or R-CHOP + LEN. Updated safety and early efficacy data will be presented at the conference. Clinical trial information: NCT04134936. [Table: see text]


Sign in / Sign up

Export Citation Format

Share Document